Literature DB >> 23964937

Tumor necrosis factor inhibitors for inflammatory bowel disease.

Ole Haagen Nielsen1, Mark Andrew Ainsworth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23964937     DOI： 10.1056/NEJMct1209614

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  100 in total

Review 1.  The Role of Neuropeptides in Mouse Models of Colitis.

Authors:  David Padua; John P Vu; Patrizia M Germano; Joseph R Pisegna
Journal:  J Mol Neurosci       Date:  2015-12-08       Impact factor: 3.444

2.  Molecular patterns in human ulcerative colitis and correlation with response to infliximab.

Authors:  Brendan Halloran; Jessica Chang; David Q Shih; Dermot McGovern; Konrad Famulski; Chad Evaschesen; Richard N Fedorak; Aducio Thiesen; Stephan Targan; Philip F Halloran
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

Review 3.  Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases.

Authors:  Ariela Holmer; Siddharth Singh
Journal:  Expert Rev Clin Immunol       Date:  2019-07-25       Impact factor: 4.473

4.  Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Dejan Micic; Yuga Komaki; Aleksandar Alavanja; David T Rubin; Atsushi Sakuraba
Journal:  J Clin Gastroenterol       Date:  2019-01       Impact factor: 3.062

Review 5.  Neuroimmune Communication in Health and Disease.

Authors:  Colin Reardon; Kaitlin Murray; Alan E Lomax
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

6.  Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNFα Therapy.

Authors:  Katrine R Christensen; Casper Steenholdt; Sine S Buhl; Mark A Ainsworth; Ole Ø Thomsen; Jørn Brynskov
Journal:  Am J Gastroenterol       Date:  2015-06-02       Impact factor: 10.864

7.  A long noncoding RNA signature for ulcerative colitis identifies IFNG-AS1 as an enhancer of inflammation.

Authors:  David Padua; Swapna Mahurkar-Joshi; Ivy Ka Man Law; Christos Polytarchou; John P Vu; Joseph R Pisegna; David Shih; Dimitrios Iliopoulos; Charalabos Pothoulakis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-08-04       Impact factor: 4.052

8.  Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.

Authors:  Siddharth Singh; Herbert C Heien; Lindsey R Sangaralingham; Stephanie R Schilz; Michael D Kappelman; Nilay D Shah; Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-04       Impact factor: 11.382

9.  The macrophage migration inhibitory factor homolog of Entamoeba histolytica binds to and immunomodulates host macrophages.

Authors:  Shannon N Moonah; Mayuresh M Abhyankar; Rashidul Haque; William A Petri
Journal:  Infect Immun       Date:  2014-05-12       Impact factor: 3.441

Review 10.  Inflammatory bowel disease: an increased risk factor for neurologic complications.

Authors:  Germán Morís
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.